Bucillamine Research for Nerve Agent Exposure: Revive Therapeutics Update
Revive Therapeutics is partnering with Defence R&D Canada (DRDC) to study Bucillamine as a potential treatment for nerve agent...
4-Year Data Shows Sustained Response to Transcon PTH Therapy
Ascendis Pharma A/S released 214-week data from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) for adults...
Galectin Therapeutics Presents NAVIGATE Trial Results at EASL 2025
Galectin Therapeutics announced positive results from its NAVIGATE trial of belapectin, a galectin-3 inhibitor, for patients with MASH cirrhosis...
Quantum Biopharma Announces Completion of Dosing in 90-Day Toxicity Study
Quantum BioPharma has completed the 90-day oral toxicity and toxicokinetic studies for its Multiple Sclerosis (MS) drug, Lucid-21-302 (Lucid-MS)....
Madera Late-breaking Phase 1/2a Trial Results at HF 2025
Medera Inc., a clinical-stage biopharmaceutical company, announced that data from its Phase 1/2a MUSIC-HFpEF clinical trial investigating its gene...
Alterity Therapeutics Shines at International MSA Congress
Alterity Therapeutics presented data at the 2025 International MSA Congress, highlighting positive Phase 2 results for their drug ATH434...
Addressing the 64% Clinical Trial Data Incompleteness Rate in Observational Research
In this interview, Rachael Thomas Higgins, Chief Commercial Officer of PicnicHealth, offers her perspective on the pivotal role of...
Cognition Therapeutics Data Shows Retinal Cell Health Impact
Cognition Therapeutics presented preclinical data at ARVO demonstrating the potential of zervimesine (CT1812) to protect retinal cells from damage...
Intranasal Foralumab Reduces Microglia in Alzheimer’s Patient
Tiziana Life SciencesLife Sciences announced positive results from a PET scan of an Alzheimer’s patient treated with their intranasal...
Akero & HistoIndex Reveal New Phase 2b Harmony Trial Analyses at EASL 2025
Akero Therapeutics announced new analyses from its 96-week Phase 2b HARMONY trial of efruxifermin (EFX) for pre-cirrhotic metabolic dysfunction-associated...